SABSW SAB Biotherapeutics Inc

Summary of Warrant Activity

The following table summarizes warrant activity for the three months ended March 31, 2024:


	Outstanding December 31, 2023		Warrants Issued		Warrants Exercised		Warrants Forfeited		Outstanding March, 31, 2024
Transaction
Business Combination Public Warrants		575,000		—		—		—		575,000
Private Placement Warrants		20,860		—		—		—		20,860
PIPE Warrants		736,337		—		—		—		736,337
PIPE Placement Agent Warrants		21,091		—		—		—		21,091
Ladenburg Warrants		30,000		—		—		—		30,000
Tranche B Warrants		42,846		—		—		—		42,846
Tranche C Warrants		107,115		—		—		—		107,115
Preferred PIPE Placement Agent Warrants		850,119		—		—		—		850,119

Tranche B Warrants [Member]

The key inputs into the valuations as of March 31, 2024 and December 31, 2023 were as follows:


	March 31, 2024			December 31, 2023
Risk-free interest rate		4.44	%		4.03	%
Expected term remaining (periods)		2.56			2.81
Implied volatility		110.0	%		85.0	%
Closing common stock price on the measurement date	$	0.45		$	0.69

The key inputs into the valuations as of the 2023 Ladenburg Agreement initial measurement date, March 21, 2023, were as follows:


	Initial Measurement
Risk-free interest rate		3.98	%
Expected term remaining (periods)		3.00
Implied volatility		94.0	%
Closing common stock price on the measurement date	$	0.52

The key inputs into the valuations as of the October 3, 2023 initial measurement date were as follows:


	Initial Measurement
Risk-free interest rate		4.80	%
Expected term remaining (periods)		5.00
Implied volatility		85.0	%
Closing common stock price on the measurement date	$	0.63

Tranche C Warrants [Member]

The key inputs utilized in determining the fair value of each Tranche B Warrants as of March 31, 2024 and December 31, 2023 were as follows:


	March 31, 2024			December 31, 2023
Risk-free interest rate (1)		2.76	%		2.58	%
Expected term remaining (periods) (1)		0.55			0.69
Implied volatility		100.0	%		85.0	%
Underlying Stock Price (Preferred Series A)	$	370.18		$	560.56

(1)

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

The key inputs utilized in determining the fair value of each Tranche C Warrants as of March 31, 2024 and December 31, 2023 were as follows:


	March 31, 2024			December 31, 2023
Risk-free interest rate (1)		4.24	%		3.85	%
Expected term remaining (periods) (1)		4.66			4.91
Implied volatility		85.0	%		85.0	%
Underlying Stock Price (Preferred Series A)	$	370.18		$	560.56

(1)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2024

Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis


	As of March 31, 2024
	Total		Quoted Prices In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Assets:
Cash equivalents
Money market funds	$	3,330,765	$	3,330,765	$	—	$	—
Short-term investments
Mutual funds		7,558,195		7,558,195		—		—
U.S. treasury securities		22,464,721		22,464,721		—		—
Long-term investments
U.S. treasury securities		1,235,150		1,235,150
Total	$	34,588,831	$	34,588,831	$	—	$	—
Liabilities:
Public Warrant liability	$	230,000	$	230,000	$	—	$	—
Private Placement Warrant liability		8,344		—		—		8,344
Preferred Warrants		6,067,672		—		—		6,067,672
Total	$	6,306,016	$	230,000	$	—	$	6,076,016


	As of December 31, 2023
	Total		Quoted Prices In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Liabilities:
Public Warrant liability	$	172,500	$	172,500	$	—	$	—
Private Placement Warrant liability		6,258		—		—		6,258
Preferred Warrants		11,595,477		—		—		11,595,477
Total	$	11,774,235	$	172,500	$	—	$	11,601,735

Private Placement Warrants [Member]

The key inputs into the valuations as of March 31, 2024 and December 31, 2023 were as follows:


	March 31, 2024			December 31, 2023
Risk-free interest rate		4.44	%		4.03	%
Expected term remaining (periods)		2.56			2.81
Implied volatility		110.0	%		85.0	%
Closing common stock price on the measurement date	$	0.45		$	0.69

The key inputs into the valuations as of the 2023 Ladenburg Agreement initial measurement date, March 21, 2023, were as follows:


	Initial Measurement
Risk-free interest rate		3.98	%
Expected term remaining (periods)		3.00
Implied volatility		94.0	%
Closing common stock price on the measurement date	$	0.52

The key inputs into the valuations as of the October 3, 2023 initial measurement date were as follows:


	Initial Measurement
Risk-free interest rate		4.80	%
Expected term remaining (periods)		5.00
Implied volatility		85.0	%
Closing common stock price on the measurement date	$	0.63

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Summary of Changes in Level 3 Fair Value Measurements

The following table provides a summary of the changes in Level 3 fair value measurements for the Private Placement Warrant liability:



Balance, December 31, 2023	$	6,258
Change in fair value of Private Placement Warrant liability		2,086
Balance, March 31, 2024	$	8,344

Preferred Warants [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Summary of Changes in Level 3 Fair Value Measurements

The following table provides a summary of the changes in Level 3 fair value measurements for the Preferred Warrant liabilities:


Balance, December 31, 2023	$	11,595,477
Change in fair value of the Preferred Warrant liabilities		(5,527,805	)
Balance, March 31, 2024	$	6,067,672

Investment Securities (Tables)

3 Months Ended

Mar. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Schedule of fair value and amortized cost of available-for-sale debt securities

The fair value and amortized cost of the Company’s available-for-sale debt securities, summarized by type of security, consisted of the following:


	As of March 31, 2024
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Short-term:
U.S. treasury securities		22,513,084		238		(48,601	)		22,464,721
Total		22,513,084		238		(48,601	)		22,464,721

Long-term:
U.S. treasury securities		1,242,848		—		(7,698	)		1,235,150
Total		1,242,848		—		(7,698	)		1,235,150

Nature of Business - Additional Information (Details) - USD ($)		2 Months Ended	3 Months Ended
	Sep. 29, 2023	Nov. 30, 2023	Mar. 31, 2024	Dec. 31, 2023
Accumulated deficit			$ 95,089,286	$ 90,063,541
Private Placement [Member] \| Securities Purchase Agreement [Member]
Sale of Stock, Consideration Received on Transaction		$ 67,100,000
Maximum [Member] \| Private Placement [Member] \| Securities Purchase Agreement [Member]
Gross proceeds from private placement	$ 110,000,000
AUSTRALIA \| SAB BIO PTY LTD [Member]
Percentage of research and development tax credit			43.50%

Summary of Significant Accounting Policies - Additional Information (Details)		3 Months Ended
	Jan. 05, 2024	Mar. 31, 2024 USD ($) Segment	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Product Information [Line Items]
Foreign currency translation adjustments		$ (33,807)
Available for sale securities		56,000
Impairment of long lived assets		$ 0	$ 0
Number of reporting segments \| Segment		1
Deferred issuance cost		$ 236,105		$ 0
Credit losses		$ 0	$ 0
Reverse stock split ratio	0.1
Maximum [Member]
Product Information [Line Items]
Vesting period of awards		10 years

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Line Items]
Equipment useful life	3 years
Animal Facility Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	7 years
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Equipment description	Shorter of asset life or lease term
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	5 years

Revenue - Additional Information (Details) - USD ($)	3 Months Ended
Revenue - Additional Information (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Aug. 01, 2019	Apr. 01, 2019	Aug. 01, 2017
Governmental Grants [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, including assessed tax	$ 945,000	$ 581,000
Federal Award [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, including assessed tax	0	192,000
Deferred revenue, total					$ 1,500,000
Geneva Foundation [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, including assessed tax	0	236,000
Deferred revenue, total						$ 2,700,000
Advanced Technology International [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, including assessed tax	$ 945,000	$ 153,000
Deferred revenue, total			$ 203,600,000	$ 25,000,000
Revenue, Remaining Performance Obligation, Percentage	9.00%

Earnings per share - Schedule of Earnings per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss attributable to the Company's shareholders	$ (5,025,745)		$ (7,353,820)
Weighted-average common shares outstanding – basic	9,241,940	9,241,940	5,039,705
Weighted-average common shares outstanding - diluted	9,241,940	9,241,940	5,039,705
Net loss per share, basic	$ (0.54)		$ (1.46)
Net loss per share, diluted	$ (0.54)		$ (1.46)

Earnings per share - Summary of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	32,942,547	1,387,781
Stock Options and Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	10,435	573,573
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	40,438	37,542
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,233,407	625,860
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	6,704,127
Preferred Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	23,803,334
Contingently Issuable Earnout Shares from Unexercised Rollover Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	150,806	150,806

Earnings per share - Summary of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss per Share (Parenthetical) (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of earnings per share	32,942,547	1,387,781
Common stock outstanding	9,229,274		9,225,494
Common stock issued	9,283,939		9,280,159
Series A-2 Convertible Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock outstanding	42,236
Common stock issued	42,236
Public Warrants [Member] \| Warrant [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of earnings per share	575,000
Private Placement Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Warrants Issued				850,119
Outstanding warrants	20,860		20,860
Private Placement Warrants [Member] \| Warrant [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of earnings per share	20,860
Ladenburg Agreement [Member] \| Warrant [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities excluded from computation of earnings per share	30,000
PIPE Private Placement Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Warrants Issued	736,337				736,337
Placement Agent Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Warrants Issued	21,091				21,091
Preferred Tranche C Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Outstanding warrants	107,115
Common stock issued	17,002,381
Preferred Tranche B Warrants [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Outstanding warrants	42,846
Common stock issued	6,800,953

Property, plant and equipment - Schedule of Property Plant and Equipment (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	$ 29,777,452	$ 29,648,378
Less: accumulated depreciation and amortization	(11,874,899)	(9,911,859)
Property, plant and equipment, net	17,902,553	19,736,519
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	9,493,096	9,415,210
Animal Facility Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	8,357,667	8,357,667
Animal Facility Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	2,899,267	1,137,666
Construction-in-Progress [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	51,188	0
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	7,064,722	9,296,344
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	208,453	208,453
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment, gross	$ 1,703,059	$ 1,233,038

Property, plant and equipment - Schedule of Property Plant and Equipment (Parenthetical) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Re-classification of property, plant and equipment	$ 2,200
Animal Facility Equipment [Member]
Property, Plant and Equipment [Line Items]
Re-classification of property, plant and equipment	1,800
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Re-classification of property, plant and equipment	$ 470

Property, plant and equipment - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 1,963,040	$ 898,453
Equipment useful life	3 years
Acquisition costs	$ 5,000
Leasehold Improvements [Member] \| Research and Development [Member]
Property, Plant and Equipment [Line Items]
Adjustment related to amortization	$ 932,000

Leases - Additional Information (Details)	1 Months Ended				3 Months Ended
Leases - Additional Information (Details)	Nov. 30, 2023 USD ($)	Jul. 31, 2022 USD ($)	Nov. 30, 2020 USD ($)	Dec. 31, 2018 USD ($) gal	Mar. 31, 2024 USD ($) Period	Mar. 31, 2023 USD ($)	Oct. 01, 2022 a
Lessee, Lease, Description [Line Items]
Finance lease payments					$ 100,000	$ 103,000
Finance lease, right-of-use asset, amortization					21,706	24,716
Operating lease payments					231,000	118,000
Finance lease interest expense					$ 68,000	69,000
Dakota Ag Properties [Member]
Lessee, Lease, Description [Line Items]
Finance lease payments				$ 34,000
Lessee finance lease interest rate				8.00%
Finance lease term				20 years
Lease payback construction cost				$ 4,000,000
Equipment [Member]
Lessee, Lease, Description [Line Items]
Finance lease payments				$ 8,000
Finance lease propane tank volume \| gal				12,000
Finance lease term				5 years
Laboratory Space [Member]
Lessee, Lease, Description [Line Items]
Lessee advanced written notice period					1 year
Office, Laboratory, and Warehouse [Member]
Lessee, Lease, Description [Line Items]
Operating lease number of option to extended additional period \| Period					3
Operating lease option to extended additional period					3 years
Operating lease cost per month	$ 31,000	$ 3,000	$ 36,000
Operating lease liablity discount rate	8.14%	6.60%	4.69%
Operating lease term					3 years
Sanford Health [Member] \| Convertible Debt [Member]
Lessee, Lease, Description [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Lease Agreement Member \| Sanford Health [Member]
Lessee, Lease, Description [Line Items]
Area of property leased \| a							21,014
Operating lease payments per month					$ 45,000
Operating lease payments per month, year one					46,000
Operating lease liablity discount rate							6.92%
Research and Development Expense [Member]
Lessee, Lease, Description [Line Items]
Operating lease expense					$ 221,000	$ 243,000

Leases - Estimated Useful Lives of Finance Lease Assets (Details)	Mar. 31, 2024
Lessee, Lease, Description [Line Items]
Estimated useful lives of the finance lease assets	3 years
Animal Facilty [Member]
Lessee, Lease, Description [Line Items]
Estimated useful lives of the finance lease assets	40 years
Equipment [Member]
Lessee, Lease, Description [Line Items]
Estimated useful lives of the finance lease assets	7 years
Equipment [Member] \| Minimum [Member]
Lessee, Lease, Description [Line Items]
Estimated useful lives of the finance lease assets	3 years
Equipment [Member] \| Maximum [Member]
Lessee, Lease, Description [Line Items]
Estimated useful lives of the finance lease assets	7 years

Leases - Schedule of Operating and Finance Leases Discount Rate (Details)	Mar. 31, 2024
Leases [Abstract]
Weighted-average remaining operating lease term	2 years 1 month 17 days
Weighted-average remaining finance lease term	14 years 8 months 1 day
Weighted-average operating lease discount rate	7.90%
Weighted-average finance discount rate	7.72%

Leases - Schedule of Undiscounted Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Operating Lease
Operating Lease 2024 - remaining	$ 509,168
Operating Lease 2025	371,957
Operating Lease 2026	309,964
Operating lease Undiscounted future minimum lease payments	1,191,089
Less:Operating Lease Amount representing interest payments	(93,701)
Total Operating lease liabilities	1,097,388
Less current portion of Operating Lease	(542,841)	$ (669,946)
Noncurrent Operating lease liabilities	554,547	635,777
Finance Lease
Finance Lease 2024 - remaining	301,122
Finance Lease 2025	401,496
Finance Lease 2026	401,496
Finance Lease 2027	401,496
Finance Lease 2028	401,496
Finance Leases Thereafter	3,981,502
Finance lease Undiscounted future minimum lease payments	5,888,608
Less: Finance lease Amount representing interest payments	(2,370,176)
Total finance lease liabilities	3,518,432
Less current portion of finance Lease	(134,568)	(132,004)
Noncurrent finance lease liabilities	$ 3,383,864	$ 3,418,483

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Payroll and employee-related costs	$ 1,919,397	$ 3,400,308
Accrued research and development expenses	641,334	480,435
Accrued legal fees	813,390	907,816
Accrued financing fees payable	1,278,000	1,461,149
Accrued interest	88,203	77,995
Other accrued expenses	433,992	364,478
Total Accrued Expenses and Other Current Liabilities	$ 5,174,316	$ 6,692,181

Notes Payable - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Oct. 01, 2022
Short-Term Debt [Line Items]
Insurance policy premiums financed, value	$ 765
Insurance policy premiums financed, interest rate	7.96%
Insurance financing note payable	$ 294	$ 509
October Note [Member] \| Sanford Health [Member]
Short-Term Debt [Line Items]
Interest rate			8.00%
Debt instrument, principal amount			$ 542
Debt instrument, conversion price per share			$ 15
Interest payable	$ 65

Stockholders' Equity - Additional Information (Details) - USD ($)					1 Months Ended		2 Months Ended	3 Months Ended
	Jan. 26, 2024	Nov. 09, 2023	Oct. 03, 2023	Sep. 29, 2023	Nov. 30, 2023	Dec. 31, 2022	Nov. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	Oct. 22, 2021
Class of Stock [Line Items]
Capital units, authorized (in shares)								810,000,000
Common stock, shares authorized (in shares)								800,000,000	800,000,000
Preferred stock, shares authorized (in shares)								10,000,000	10,000,000
Preferred stock, par value								$ 0.0001	$ 0.0001
Shares exercised during the period								3,780
Preferred stock, shares issued (in shares)								42,236	42,236
Preferred stock, shares outstanding (in shares)								42,236	42,236
Earnout shares at fair value								1,200,000
Earnout value at fair value								$ 101,300,000
Preferred Tranche A Warrants [Member]
Class of Stock [Line Items]
Warrants exercisable, description								The Preferred Tranche A Warrants became exercisable beginning on October 2, 2023, (the “Issuance Date”) until the earlier of (i) fifteen (15) trading days following the date of the public announcement of the fulsome data set from the Sanofi S.A. Protect trial or (ii) December 15, 2023. If any purchaser in the September 2023 Offering failed to exercise their Preferred Tranche A Warrant in full prior to its expiration date, such purchaser
Preferred Tranche B Warrants [Member]
Class of Stock [Line Items]
Warrants exercisable, description								The Preferred Tranche B Warrants became exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche B Warrant) until the later of (i) 15 days following the Company’s announcement of data from its SAB-142-101 clinical trial and (ii) March 31, 2025.
Preferred Tranche C Warrants [Member]
Class of Stock [Line Items]
Warrants exercisable, description								The Preferred Tranche C Warrants became exercisable commencing on the Exercisability Date (as defined in the Form of Preferred Tranche C Warrant) until the five (5) year anniversary of the Exercisability Date.
2023 Private Placement [Member
Class of Stock [Line Items]
Aggregate offering price from agreement						$ 8,000,000
Stock issued during period, shares, new issues (in shares)						736,337
2023 Private Placement [Member \| Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of Stock, Consideration Received on Transaction							$ 67,100,000
2023 Private Placement [Member \| Securities Purchase Agreement [Member] \| Preferred Tranche A Warrants [Member]
Class of Stock [Line Items]
Preferred stock, par value				$ 0.0001
Aggregate exercise price				$ 70,500,000
Shares exercised during the period		16,269
Warrants Issued		27,115
2023 Private Placement [Member \| Securities Purchase Agreement [Member] \| Preferred Tranche B Warrants [Member]
Class of Stock [Line Items]
Preferred stock, par value				$ 0.0001
Aggregate exercise price				$ 52,000,000
Shares exercised during the period		10,846
2023 Private Placement [Member \| Securities Purchase Agreement [Member] \| Preferred Tranche C Warrants [Member]
Class of Stock [Line Items]
Preferred stock, par value				$ 0.0001
Aggregate exercise price				$ 130
Shares exercised during the period		27,115
Sales Agreement [Member]
Class of Stock [Line Items]
Aggregate offering price from agreement	$ 20,000,000
Stock issued during period, shares, new issues (in shares)								0
Common Stock [Member] \| Big Cypress Acquisition Corp [Member]
Class of Stock [Line Items]
Contingent right to receive pro rate portion of earn out shares										1,200,000
Earn out shares, contingently issuable										150,806
Contingent right earn out shares, outstanding										1,049,194
Series A-2 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value				$ 0.0001
Series A One Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value				$ 6.3	$ 0.0001		$ 0.0001
Stock issued during period, shares, conversion of units								67,154
Contingent right to receive pro rate portion of earn out shares					3,954,674		3,954,674
Series A One Convertible Preferred Stock [Member] \| Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Gross proceeds from private placement				$ 7,500,000
Series A One Convertible Preferred Stock [Member] \| 2023 Private Placement [Member
Class of Stock [Line Items]
Stock issued during period, shares, conversion of units								24,918
Series A One Convertible Preferred Stock [Member] \| 2023 Private Placement [Member \| Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued		59,654	7,500	7,500
Preferred stock, par value				$ 0.0001
Sale of Stock, Consideration Received on Transaction				$ 7,500,000
Aggregate exercise price		$ 59,650,000
Net proceeds from private placement			$ 7,500,000
Warrants, value			10,900,000
Fair value of warrants exceeded equity proceeds loss on issuance			$ 3,400,000
Series A One Convertible Preferred Stock [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Conversion of Preferred Stock into common shares (in shares)								3,954,674
Series A-2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Preferred Stock into common shares (in shares)					42,236			42,236
First Earnout [Member]
Class of Stock [Line Items]
Percentage of earn out shares to be released								25.00%
Period to issue earn out shares (year)								5 years
Volume weighted average price threshold (in dollars per share)								$ 150
Shareholders equity volume weighted average price threshold trading days (day)								20 years
Shareholders equity volume weighted average price threshold consecutive trading days (day)								30 years
Second Earnouts [Member]
Class of Stock [Line Items]
Percentage of earn out shares to be released								25.00%
Period to issue earn out shares (year)								5 years
Volume weighted average price threshold (in dollars per share)								$ 200
Shareholders equity volume weighted average price threshold trading days (day)								20 years
Shareholders equity volume weighted average price threshold consecutive trading days (day)								30 years
Third Earnouts [Member]
Class of Stock [Line Items]
Percentage of earn out shares to be released								25.00%
Period to issue earn out shares (year)								5 years
Volume weighted average price threshold (in dollars per share)								$ 250
Shareholders equity volume weighted average price threshold trading days (day)								20 years
Shareholders equity volume weighted average price threshold consecutive trading days (day)								30 years
Fourth Earnouts [Member]
Class of Stock [Line Items]
Percentage of earn out shares to be released								25.00%
Period to issue earn out shares (year)								5 years
Volume weighted average price threshold (in dollars per share)								$ 300
Shareholders equity volume weighted average price threshold trading days (day)								20 years
Shareholders equity volume weighted average price threshold consecutive trading days (day)								30 days

Stock Option Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Estimated weighted average amortization period	3 years 7 months 6 days
Unrecognized compensation expense	$ 6,800
Number of stock options granted	1,084,000
Option vested fair value	$ 700	$ 600
Number of stock options vested	88,336	21,362
Weighted average grant date fair value of options granted	$ 3.94	$ 3.86
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Estimated weighted average amortization period	2 years 7 months 6 days
Unrecognized equity-based compensation	$ 454
Fair Value of shares vested	$ 80
Number of shares vested	22,978
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares vested	22,978
Restricted Stock Units (RSUs) [Member] \| Vested with a Fair Value of Eighty Thousand [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares vested	10,162
2014 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	728,650
Common stock available for grant	143,755
Number of stock options granted	584,895
Omnibus Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	1,100,000
Common stock reserved for future issuance increased, percentage	2.00%
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	1,600,000
Common stock available for grant	43,296
Number of stock options granted	1,556,704
Additional Shares available for issuance not exceed	500,000

Stock Option Plans - Summary of Stock Options (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of Stock Options Outstanding, Beginning of Period	1,009,519
Number of Stock Options, Granted	1,084,000
Number of Stock Options, Forfeited	(1,249)
Number of Stock Options, Exercised	(3,780)
Number of Stock Options, Expired	(13,778)
Number of Stock Options Outstanding, End of Period	2,074,712	1,009,519
Options vested and exercisable, March 31, 2024	583,743
Weighted Average Exercise Price Per Share, Beginning of Period	$ 15.01
Weighted Average Exercise Price Per Share, Granted	5.15
Weighted Average Exercise Price Per Share, Forfeited	6.05
Weighted Average Exercise Price Per Share, Exercised	5.4
Weighted Average Exercise Price Per Share, Expired	51.1
Weighted Average Exercise Price, End of Period	9.64	$ 15.01
Weighted Average Exercise Price, Options vested and exercisable at March 31,2024	$ 18.29
Weighted-Average Remaining Contractual Life (years), Options outstanding	8 years 21 days	6 years 2 months 8 days
Weighted-Average Remaining Contractual Life (years), Options vested and exercisable at March 31, 2024	4 years 18 days
Aggregate Intrinsic Value, Options outstanding		$ 664,967

Stock Option Plans - Summary of Assumptions Used to Calculate Estimated Fair Value of Stock Options (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility		81.90%
Expected volatility, minimum	89.90%
Expected volatility, maximum	90.40%
Weighted-average volatility	89.90%	81.90%
Risk-free rate, minimum	4.26%	3.76%
Risk-free rate, maximum	4.32%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	5 years 8 months 23 days	6 years 29 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)	6 years 29 days

Stock Option Plans - Summary of Assumptions Used to Calculate Estimated Fair Value of Stock Options (Parenthetical) (Details)	3 Months Ended
	Mar. 31, 2024 shares
Share-Based Payment Arrangement [Abstract]
Number of stock options granted	1,084,000

Stock Option Plans - Summary of Restricted Stock (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of unvested shares, Beginning of Period \| shares	54,071
Number of shares,Vested \| shares	(22,978)
Number of unvested shares, End of Period \| shares	31,093
Weighted Average Grant Date Fair Value, Beginning of Period \| $ / shares	$ 11.56
Weighted Average Grant Date Fair Value, Vested \| $ / shares	13.23
Weighted Average Grant Date Fair Value, End of Period \| $ / shares	$ 11.56

Stock Option Plans - Schedule of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 617,445	$ 602,780
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	216,351	147,691
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 401,094	$ 455,089

Warrants - Additional Information (Details) - USD ($)					1 Months Ended	3 Months Ended
Warrants - Additional Information (Details) - USD ($)	Dec. 31, 2023	Sep. 29, 2023	Jun. 30, 2023	Mar. 21, 2023	Dec. 31, 2022	Mar. 31, 2024	Nov. 30, 2023	Nov. 21, 2023	Oct. 03, 2023
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, term (year)	2 years 9 months 21 days					2 years 6 months 21 days			5 years
PIPE Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 10.8	$ 10.8
Warrants Issued					736,337	736,337
Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 13.5	$ 13.5
Warrants Issued					21,091	21,091
Warrants and rights outstanding, term (year)					5 years
Warrants or right, issued, percentage of shares purchased					7.00%
Ladenburg Agreement Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 5.424		$ 5.424
Stock issued during period, shares, new issues (in shares)			191,689
Warrants Issued				30,000
Warrants and rights outstanding, term (year)				3 years
Stock issued	$ 1,100,000		$ 1,500,000	$ 500,000
Cash payment to settle warrants						$ 1,100,000
Warrants and rights outstanding, fair value per share (in dollars per share)						$ 3.1
Warrants, value						$ 93,000
Preferred Tranche B Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding warrants						42,846
Preferred Tranche C Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding warrants						107,115
Preferred PIPE Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)								$ 6.3
Warrants Issued								850,119
Outstanding warrants	850,119					850,119
Preferred Placement Agent Warrant [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)							$ 6.3
Warrants and rights outstanding, fair value per share (in dollars per share)						$ 4.4
Preferred Placement Agent Warrant [Member] \| Additional Paid-In Capital [Member]
Class of Warrant or Right [Line Items]
Warrants, value						$ 3,700,000
Private Placement [Member]
Class of Warrant or Right [Line Items]
Stock issued during period, shares, new issues (in shares)					736,337
Equity offering, combined purchase price (in dollars per share)					$ 10.8
Equity offering, premium per share (in dollars per share)					$ 1.25
Warrants and rights outstanding, term (year)					5 years
Placement agent fee, percentage of gross proceeds					7.00%
Proceeds from issuance or sale of equity					$ 8,000,000
Private Placement [Member] \| Preferred Tranche B Warrants [Member] \| Securities Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Aggregate exercise price		$ 52,000,000
Private Placement [Member] \| Preferred Tranche B Warrants [Member] \| Securities Purchase Agreement [Member] \| Series A-3 Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Outstanding warrants						42,846
Aggregate exercise price						$ 42,850,000
Private Placement [Member] \| Preferred Tranche C Warrants [Member] \| Securities Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Aggregate exercise price		$ 130
Private Placement [Member] \| Preferred Tranche C Warrants [Member] \| Securities Purchase Agreement [Member] \| Series A-3 Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Outstanding warrants						107,115
Aggregate exercise price						$ 107,100,000
Public Warrants [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by each warrant or right (in shares)						1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)						$ 115
Warrants or rights, redemption price (in dollars per share)						0.01
Warrants and rights outstanding, minimum share price to call (in dollars per share)						$ 180

Warrants - Summary of Warrant Activity (Details)	Mar. 31, 2024 shares
Business Combination Public Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	575,000
Outstanding, Ending Balance	575,000
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	20,860
Outstanding, Ending Balance	20,860
PIPE Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	736,337
Outstanding, Ending Balance	736,337
PIPE Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	21,091
Outstanding, Ending Balance	21,091
Ladenburg Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	30,000
Outstanding, Ending Balance	30,000
Tranche B Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	42,846
Outstanding, Ending Balance	42,846
Tranche C Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	107,115
Outstanding, Ending Balance	107,115
Preferred PIPE Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning Balance	850,119
Outstanding, Ending Balance	850,119

Warrants - Schedule of Key Inputs into Monte Carlo Simulation (Details)

Mar. 31, 2024

Dec. 31, 2023

Oct. 03, 2023

Mar. 21, 2023

Measurement Input, Risk Free Interest Rate [Member]

2 years 6 months 21 days

2 years 9 months 21 days

5 years

Measurement Input, Option Volatility [Member]

0.0444

0.0403

Measurement Input, Share Price [Member]

1.10

0.85

Tranche B Warrants [Member]

0.0045

0.0069

0.0063

Tranche B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]

^[1]

6 months 18 days

8 months 8 days

Tranche B Warrants [Member] | Measurement Input, Option Volatility [Member]

^[1]

0.0276

0.0258

Tranche B Warrants [Member] | Preferred Series A [Member] | Measurement Input, Share Price [Member]

0.85

Tranche C Warrants [Member]

3.7018

5.6056

Tranche C Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]

^[2]

4 years 7 months 28 days

4 years 10 months 28 days

Tranche C Warrants [Member] | Measurement Input, Option Volatility [Member]

^[2]

0.0424

0.0385

Tranche C Warrants [Member] | Preferred Series A [Member] | Measurement Input, Share Price [Member]

0.85

Ladenburg Agreement [Member]

3.7018

5.6056

Ladenburg Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]

3 years

Ladenburg Agreement [Member] | Measurement Input, Option Volatility [Member]

0.0398

Ladenburg Agreement [Member] | Measurement Input, Share Price [Member]

0.94

Preferred Placement Agent Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]

0.0052